Results 111 to 120 of about 350 (140)
Some of the next articles are maybe not open access.
Razoxane (ICRF 159) in the treatment of psoriasis
British Journal of Dermatology, 1980This paper describes our experience with the use of razoxane (ICRF 159), a new anti-mitotic drug, in the treatment of thirty-six patients with severe psoriasis. The drug has proven highly effective both in cutaneous and in arthropathic disease. The drug is well tolerated by patients and appears to be free of hepatotoxicity.
D J, Atherton +3 more
openaire +2 more sources
Effect of razoxane on metastases from colorectal cancer
Clinical & Experimental Metastasis, 1987At a median follow-up of 5 years, adjuvant razoxane (125 mg b.d.) given 5 days/week indefinitely following resection of colorectal cancer provided no benefit in terms of survival or recurrence for Dukes' A or B patients when compared to untreated controls.
K, Hellmann +4 more
openaire +2 more sources
Antimetastatic effects of razoxane in a rat osteosarcoma model
Clinical & Experimental Metastasis, 1987The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.
F, Wingen, H, Spring, D, Schmähl
openaire +2 more sources
Razoxane: a review of 6 years' therapy in psoriasis
British Journal of Dermatology, 1983Razoxane is an effective drug in the systemic treatment of psoriasis, with an initial response rate of 97%. After continuous therapy for up to 6 years we found that 72% of patients remained on the drug with a good therapeutic benefit. We found it to be useful in all forms of cutaneous psoriasis and psoriatic arthropathy.
J J, Horton, R S, Wells
openaire +2 more sources
Acute myeloid leukaemia after treatment with razoxane
British Journal of Dermatology, 1985Two new cases of acute myeloid leukaemia occurring after razoxane therapy are recorded and further haematological and cytogenetic details of two cases previously reported are described. The need for long-term follow-up after patients discontinue razoxane therapy is emphasized.
E A, Caffrey, M G, Daker, J J, Horton
openaire +2 more sources
Epitheliomas in patients receiving razoxane therapy for psoriasis
British Journal of Dermatology, 1983We report two cases in which cutaneous squamous cell carcinomata developed in patients with psoriasis on razoxane therapy. The relevance of razoxane as well as past treatment for psoriasis in the aetiology of these tumours is discussed.
J J, Horton, D M, MacDonald, R S, Wells
openaire +2 more sources
Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus
International Journal of Radiation Oncology*Biology*Physics, 1979Abstract One hundred thirteen patients with inoperable carcinoma of the bronchus were ramdomly allocated to receive either radiotherapy or radiotherapy plus razoxane. They were stratified according to histology and analyzed according to whether they had oat-cell or non oat-cell carcinomas and whether they tolerated only 1 course (3,000 rad) or 2 ...
M F, Spittle +3 more
openaire +2 more sources
Psoriasis, razoxane and a cutaneous B-cell lymphoma
British Journal of Dermatology, 1987A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a B-cell lymphoma of the lip following 4 1/2 years of treatment with razoxane.
R B, Mallett +3 more
openaire +2 more sources
Razoxane - a new anti-tumour agent
Drug and Therapeutics Bulletin, 1978Razoxane (Razoxin - ICI; ICRF 159) is a new anti-tumour drug which is claimed to be well tolerated, to possess unusual modes of action and to increase the effectiveness of radiotherapy.
openaire +3 more sources
Responses of liver metastases to radiotherapy and razoxane.
Journal of the Royal Society of Medicine, 1992Twenty-five patients with liver metastases, chiefly due to colorectal cancer, were given a loading dose of razoxane for 3 days before 5 consecutive days of radiotherapy to the whole liver. Patients also took razoxane during the radiotherapy and then for one month afterwards.
K, Hellmann +3 more
openaire +1 more source